Back to Editor profile » Dr Ebrahim Mostafavi

Dr Ebrahim Mostafavi

Dr Ebrahim Mostafavi

Associate Editor: Dr. Ebrahim Mostafavi

Dr. Ebrahim Mostafavi has so far received training at Stanford Cardiovascular Institute, Stanford University School of Medicine (PostDoc), Northeastern University (Ph.D.), Harvard Medical School (Researcher), and University of Tehran (M.Sc. and B.Sc.). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as tissue engineering and regenerative medicine, translational medicine, cancer therapy (with focus on women’s cancer), biosensing, and infectious diseases. Dr. Mostafavi serves as Associate Editor-in-Chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, etc. He is also an Editorial Board Member of 25+ impactful and prestigious biomedical and materials science journals. His scholarly work comprises >145 publications with an H-index of 28 (i10-index= 75), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, Global Health, etc.) and JAMA Network (Oncology, Cardiology) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/translational medicine.

Updated 16 December 2022